NO20065502L - Farmasoytiske sammensetninger. - Google Patents

Farmasoytiske sammensetninger.

Info

Publication number: NO20065502L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; relates; present; glycopyrrolate; antimuscarinic
Prior art date: 2004-04-30

Application number

NO20065502A

Other languages

English (en)

Norwegian (no)

Inventor

David Morton

Martin Shott

Rebecca Davies

Original Assignee

Vectura Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-30

Filing date

2006-11-29

Publication date

2007-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065502(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-11-29 Application filed by Vectura Ltd filed Critical Vectura Ltd

2007-01-24 Publication of NO20065502L publication Critical patent/NO20065502L/no

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 2
230000001022 anti-muscarinic effect Effects 0.000 abstract 1
229940015042 glycopyrrolate Drugs 0.000 abstract 1
229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000000843 powder Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20065502A 2004-04-30 2006-11-29 Farmasoytiske sammensetninger. NO20065502L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0409703.6A GB0409703D0 (en)	2004-04-30	2004-04-30	Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en)	2004-04-30	2005-04-29	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
NO20065502L true NO20065502L (no)	2007-01-24

Family

ID=32408337

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20065502A NO20065502L (no)	2004-04-30	2006-11-29	Farmasoytiske sammensetninger.

Country Status (26)

Country	Link
US (1)	US20080063719A1 (lt)
EP (3)	EP1755555B1 (lt)
JP (2)	JP5000483B2 (lt)
KR (1)	KR101287919B1 (lt)
CN (3)	CN102008453A (lt)
AU (2)	AU2005237266B2 (lt)
BR (1)	BRPI0510500B8 (lt)
CA (1)	CA2563760C (lt)
CY (6)	CY1113069T1 (lt)
DK (2)	DK2422766T3 (lt)
ES (2)	ES2546982T3 (lt)
GB (1)	GB0409703D0 (lt)
HU (4)	HUE025463T2 (lt)
IL (2)	IL178651A (lt)
LT (1)	LTC2422766I2 (lt)
LU (2)	LU92176I2 (lt)
MX (2)	MXPA06012493A (lt)
NO (1)	NO20065502L (lt)
NZ (1)	NZ550479A (lt)
PL (2)	PL1755555T3 (lt)
PT (2)	PT2422766E (lt)
RU (1)	RU2396943C2 (lt)
SG (3)	SG10201605001SA (lt)
SI (2)	SI2422766T1 (lt)
WO (1)	WO2005105043A2 (lt)
ZA (1)	ZA200609350B (lt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0409703D0 (en) *	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
GB0425758D0 (en) *	2004-11-23	2004-12-22	Vectura Ltd	Preparation of pharmaceutical compositions
GB0525254D0 (en) *	2005-12-12	2006-01-18	Jagotec Ag	Powder compositions for inhalation
GB0613161D0 (en)	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
EP2234595B1 (en) *	2007-12-13	2012-11-28	Novartis AG	Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
WO2009074666A1 (en) *	2007-12-13	2009-06-18	Novartis Ag	Organic compounds
US20100055045A1 (en)	2008-02-26	2010-03-04	William Gerhart	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
GB2468073B (en) *	2008-02-26	2012-09-05	Elevation Pharmaceuticals Inc	Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
LT2400950T (lt)	2009-02-26	2019-08-26	Glaxo Group Limited	Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
US20120101077A1 (en) *	2009-04-24	2012-04-26	Schering Corporation	Agglomerate formulations useful in dry powder inhalers
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
GB0921481D0 (en) *	2009-12-08	2010-01-20	Vectura Ltd	Process and product
WO2011121425A1 (en) *	2010-03-31	2011-10-06	Glenmark Pharmaceuticals Limited	Pharmaceutical powder composition for inhalation
BR112012024059B1 (pt)	2010-04-01	2021-06-01	Chiesi Farmaceutici S.P.A.	Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
WO2011131663A1 (en) *	2010-04-21	2011-10-27	Chiesi Farmaceutici S.P.A.	"process for providing particles with reduced electrostatic charges"
AU2011298315B2 (en)	2010-08-31	2014-08-28	Glaxo Group Limited	Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US20130156828A1 (en)	2010-08-31	2013-06-20	Osama Ahmed Aswania	Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
JO3510B1 (ar) *	2011-03-04	2020-07-05	Heptares Therapeutics Ltd	استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
RU2666963C2 (ru)	2012-04-13	2018-09-13	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Агрегированные частицы
AU2013100007B4 (en) *	2013-01-04	2013-05-23	Novartis Ag	System for treating chronic obstructive pulmonary disease
US9006462B2 (en)	2013-02-28	2015-04-14	Dermira, Inc.	Glycopyrrolate salts
EP3473615B1 (en)	2013-02-28	2022-01-19	Journey Medical Corporation	Glycopyrrolate salts
US8558008B2 (en)	2013-02-28	2013-10-15	Dermira, Inc.	Crystalline glycopyrrolate tosylate
KR102391332B1 (ko) †	2013-03-15	2022-04-26	펄 테라퓨틱스 인코포레이티드	미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
GB201305825D0 (en)	2013-03-28	2013-05-15	Vectura Ltd	New use
US9393202B2 (en) *	2013-04-26	2016-07-19	Chiesi Farmaceutici S.P.A	Particle size reduction of an antimuscarinic compound
GB201402556D0 (en)	2014-02-13	2014-04-02	Crystec Ltd	Improvements relating to inhalable particles
SMT202000280T1 (it)	2014-09-09	2020-07-08	Vectura Ltd	Formulazione comprendente glicopirrolato, metodo ed apparecchiatura
KR20170068571A (ko)	2014-10-16	2017-06-19	테바 브랜디드 파마슈티컬 프로덕츠 알앤디, 인코포레이티드	건조 분말 제제
US9925168B2 (en)	2016-01-22	2018-03-27	Chiesi Farmaceutici S.P.A.	Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
BR112018067454A2 (pt)	2016-03-08	2019-01-15	Mereo Biopharma 1 Ltd	regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica
AU2016397046B2 (en)	2016-03-08	2022-05-12	Mereo Biopharma 1 Limited	Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
EP3490533B1 (en)	2016-07-29	2020-05-27	Inke, S.A.	Particle size stabilization process
MX387723B (es)	2016-09-19	2025-03-18	Mexichem Fluor Sa De Cv	Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
ES3009923T3 (en)	2017-03-15	2025-03-31	Vectura Ltd	Method and formulation
WO2019060604A1 (en) *	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE MEDICINE
WO2019060595A1 (en)	2017-09-20	2019-03-28	Teva Branded Pharmaceutical Products R&D, Inc.	INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
HUE054266T2 (hu)	2017-12-11	2021-08-30	Mereo Biopharma 1 Ltd	3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
AU2018382895B2 (en)	2017-12-11	2024-05-16	Mereo Biopharma 1 Limited	Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko)	2018-12-21	2024-08-20	한미약품 주식회사	흡입 제형용 건조 분말 및 이의 제조방법
WO2023117967A1 (en)	2021-12-21	2023-06-29	Chiesi Farmaceutici S.P.A.	Dry powder formulations filled in an inhaler with improved resistance to humidity
EP4452223A1 (en)	2021-12-21	2024-10-30	Chiesi Farmaceutici S.p.A.	Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2956062A (en) *	1959-02-26	1960-10-11	Robins Co Inc A H	Esters of amino alcohols
US3709039A (en) *	1970-08-31	1973-01-09	Gen Time Corp	Comfort humidity indicator
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) *	1995-04-07	1997-03-18	Edward Mendell Co., Inc.	Controlled release insufflation carrier for medicaments
GB9808470D0 (en)	1998-04-22	1998-06-17	Smithkline Beecham Plc	Novel process and apparatus
AU756852B2 (en)	1998-11-13	2003-01-23	Jagotec Ag	Dry powder for inhalation
GB9826284D0 (en) *	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
GB9826286D0 (en)	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
GB0008660D0 (en) *	2000-04-07	2000-05-31	Arakis Ltd	The treatment of respiratory diseases
PE20011227A1 (es)	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1296651E (pt)	2000-06-27	2008-02-12	Vectura Ltd	Método para fazer partículas para serem usadas numa composição farmacêutica
EP2283818B1 (en) *	2000-11-30	2017-08-02	Vectura Limited	Method of making particles for use in a pharmaceutical composition
NZ526059A (en) *	2000-11-30	2005-05-27	Vectura Ltd	Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
NZ528640A (en) *	2001-03-30	2004-06-25	Jagotec Ag	Medical aerosol formulations
EP1501479A1 (en) *	2002-05-07	2005-02-02	Nektar Therapeutics	Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) *	2003-09-15	2005-03-16	Vectura Ltd	Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) *	2004-04-30	2004-06-02	Vectura Ltd	Pharmaceutical compositions
EP1861361A1 (en) *	2005-03-24	2007-12-05	Sosei R&D Ltd.	Glycopyrronium salts and their therapeutic use

2004
- 2004-04-30 GB GBGB0409703.6A patent/GB0409703D0/en not_active Ceased
2005
- 2005-04-29 BR BRPI0510500A patent/BRPI0510500B8/pt not_active IP Right Cessation
- 2005-04-29 SI SI200531999T patent/SI2422766T1/sl unknown
- 2005-04-29 PT PT111906376T patent/PT2422766E/pt unknown
- 2005-04-29 DK DK11190637.6T patent/DK2422766T3/da active
- 2005-04-29 EP EP05738040A patent/EP1755555B1/en not_active Revoked
- 2005-04-29 CN CN2010105642463A patent/CN102008453A/zh active Pending
- 2005-04-29 SI SI200531570T patent/SI1755555T1/sl unknown
- 2005-04-29 NZ NZ550479A patent/NZ550479A/en not_active IP Right Cessation
- 2005-04-29 RU RU2006142322/15A patent/RU2396943C2/ru active Protection Beyond IP Right Term
- 2005-04-29 JP JP2007510045A patent/JP5000483B2/ja not_active Expired - Lifetime
- 2005-04-29 AU AU2005237266A patent/AU2005237266B2/en active Active
- 2005-04-29 US US11/587,725 patent/US20080063719A1/en not_active Abandoned
- 2005-04-29 PL PL05738040T patent/PL1755555T3/pl unknown
- 2005-04-29 WO PCT/EP2005/051980 patent/WO2005105043A2/en not_active Ceased
- 2005-04-29 HU HUE11190637A patent/HUE025463T2/en unknown
- 2005-04-29 KR KR1020067024763A patent/KR101287919B1/ko not_active Expired - Lifetime
- 2005-04-29 SG SG10201605001SA patent/SG10201605001SA/en unknown
- 2005-04-29 EP EP11190638A patent/EP2422767A3/en not_active Withdrawn
- 2005-04-29 CA CA2563760A patent/CA2563760C/en not_active Expired - Lifetime
- 2005-04-29 ES ES11190637.6T patent/ES2546982T3/es not_active Expired - Lifetime
- 2005-04-29 CN CNA200580013592XA patent/CN1964700A/zh active Pending
- 2005-04-29 EP EP11190637.6A patent/EP2422766B1/en not_active Revoked
- 2005-04-29 PL PL11190637T patent/PL2422766T3/pl unknown
- 2005-04-29 CN CN201710357916.6A patent/CN107252423A/zh active Pending
- 2005-04-29 MX MXPA06012493A patent/MXPA06012493A/es active IP Right Grant
- 2005-04-29 PT PT05738040T patent/PT1755555E/pt unknown
- 2005-04-29 SG SG200903001-6A patent/SG152292A1/en unknown
- 2005-04-29 SG SG2012093886A patent/SG186673A1/en unknown
- 2005-04-29 ES ES05738040T patent/ES2388289T3/es not_active Expired - Lifetime
- 2005-04-29 DK DK05738040.4T patent/DK1755555T3/da active
2006
- 2006-10-16 IL IL178651A patent/IL178651A/en active IP Right Review Request
- 2006-10-27 MX MX2012008068A patent/MX341426B/es unknown
- 2006-11-10 ZA ZA2006/09350A patent/ZA200609350B/en unknown
- 2006-11-29 NO NO20065502A patent/NO20065502L/no not_active Application Discontinuation
2011
- 2011-02-09 AU AU2011200543A patent/AU2011200543B2/en not_active Expired
- 2011-11-08 JP JP2011244443A patent/JP5124718B2/ja not_active Expired - Lifetime
2012
- 2012-08-13 CY CY20121100722T patent/CY1113069T1/el unknown
- 2012-12-10 IL IL223545A patent/IL223545A/en active IP Right Grant
2013
- 2013-03-13 HU HUS1300006C patent/HUS1300006I1/hu unknown
- 2013-03-27 LU LU92176C patent/LU92176I2/fr unknown
- 2013-03-29 CY CY2013012C patent/CY2013012I2/el unknown
2014
- 2014-03-07 LU LU92392C patent/LU92392I2/xx unknown
- 2014-03-19 CY CY2014015C patent/CY2014015I2/el unknown
2015
- 2015-08-27 CY CY20151100754T patent/CY1116655T1/el unknown
- 2015-12-18 LT LTPA2015053C patent/LTC2422766I2/lt unknown
- 2015-12-21 HU HUS1500073C patent/HUS1500073I1/hu unknown
- 2015-12-21 HU HUS1500072C patent/HUS1500072I1/hu unknown
- 2015-12-23 CY CY2015060C patent/CY2015060I1/el unknown
- 2015-12-23 CY CY2015059C patent/CY2015059I1/el unknown

Also Published As

Publication number	Publication date
CY1116655T1 (el)	2017-03-15
HK1167334A1 (en)	2012-11-30
MX341426B (es)	2016-08-18
JP5000483B2 (ja)	2012-08-15
BRPI0510500B8 (pt)	2021-05-25
DK1755555T3 (da)	2012-08-20
EP2422767A2 (en)	2012-02-29
BRPI0510500B1 (pt)	2019-04-24
PT2422766E (pt)	2015-10-12
ES2546982T3 (es)	2015-09-30
HUE025463T2 (en)	2016-02-29
PL1755555T3 (pl)	2012-11-30
WO2005105043A2 (en)	2005-11-10
KR101287919B1 (ko)	2013-07-18
HK1095282A1 (en)	2007-05-04
HUS1500072I1 (hu)	2016-02-29
CN107252423A (zh)	2017-10-17
RU2396943C2 (ru)	2010-08-20
CY2014015I1 (el)	2015-12-09
SI1755555T1 (sl)	2012-10-30
LU92392I2 (fr)	2015-11-02
CY2015059I1 (el)	2020-05-29
EP2422766A2 (en)	2012-02-29
EP1755555B1 (en)	2012-05-23
ZA200609350B (en)	2008-04-30
LU92176I2 (fr)	2013-05-27
NZ550479A (en)	2009-11-27
CA2563760A1 (en)	2005-11-10
WO2005105043A3 (en)	2006-05-04
JP2012031209A (ja)	2012-02-16
DK2422766T3 (da)	2015-08-31
JP5124718B2 (ja)	2013-01-23
JP2007535522A (ja)	2007-12-06
PT1755555E (pt)	2012-08-17
RU2006142322A (ru)	2008-06-20
MXPA06012493A (es)	2007-01-29
CY2014015I2 (el)	2015-12-09
KR20070033978A (ko)	2007-03-27
CA2563760C (en)	2013-07-02
AU2011200543A1 (en)	2011-03-03
AU2011200543A8 (en)	2011-03-31
IL223545A0 (en)	2013-02-03
LU92176I9 (lt)	2019-01-04
US20080063719A1 (en)	2008-03-13
HUS1300006I1 (hu)	2016-07-28
SG186673A1 (en)	2013-01-30
GB0409703D0 (en)	2004-06-02
PL2422766T3 (pl)	2015-11-30
IL223545A (en)	2016-04-21
EP2422767A3 (en)	2012-04-25
CY1113069T1 (el)	2015-08-05
AU2011200543B2 (en)	2012-11-29
EP1755555A2 (en)	2007-02-28
IL178651A (en)	2012-12-31
CY2013012I1 (el)	2015-08-05
HUS1500073I1 (hu)	2016-02-29
BRPI0510500A (pt)	2007-10-30
AU2005237266A1 (en)	2005-11-10
AU2005237266B2 (en)	2010-11-11
CN102008453A (zh)	2011-04-13
LTC2422766I2 (lt)	2020-02-10
SI2422766T1 (sl)	2015-10-30
CY2013012I2 (el)	2015-08-05
CY2015060I1 (el)	2020-05-29
EP2422766B1 (en)	2015-06-24
IL178651A0 (en)	2007-02-11
SG10201605001SA (en)	2016-08-30
EP2422766A3 (en)	2012-04-25
SG152292A1 (en)	2009-05-29
ES2388289T3 (es)	2012-10-11
CN1964700A (zh)	2007-05-16

Legal Events

Date	Code	Title	Description
2020-03-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20065502L (no)	2007-01-24	Farmasoytiske sammensetninger.
NO20083147L (no)	2008-09-16	Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20090047L (no)	2009-03-05	Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20073628L (no)	2007-07-16	Pyridoner som er nyttige som inhibitorer av kinaser
DK1682530T3 (da)	2007-07-16	Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20076046L (no)	2008-01-30	Bindemidler
NO20081160L (no)	2008-05-29	Benzimidazoltiofen forbindelser
ZA200709691B (en)	2009-09-30	N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
NO20083397L (no)	2008-10-02	Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MX348432B (es)	2017-06-05	Epitopes.
DK1863812T3 (da)	2010-10-18	Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
TW200519089A (en)	2005-06-16	Biaryl sulfonamides and methods for using same
NO20071823L (no)	2007-06-11	Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
NO20082298L (no)	2008-07-17	Kaliumkanalinhibitorer
DE602004010164D1 (de)	2007-12-27	Capsaicinderivate und deren produktion und verwendung
TW200519100A (en)	2005-06-16	Biaryl sulfonamides and methods for using same
NO20083593L (no)	2008-10-17	Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20075140L (no)	2007-12-07	Fremgangsmater og preparater for modulering av vaskulaer integritet
TW200716622A (en)	2007-05-01	Substituted piperidines
EA200801414A1 (ru)	2008-10-30	Кальцилитические соединения
WO2006079057A3 (en)	2007-02-01	Methods and compositions for specific inhibition of protein splicing by small molecules
MX2007002917A (es)	2007-07-11	Todo-trans-retinol: todo-trans-13, 14-dihidrorretinol saturasa y metodos de uso de la misma.
DK1594868T3 (da)	2010-03-15	8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer
EA200701688A1 (ru)	2007-12-28	Замещённые пирролы, содержащие их композиции, способ получения и применение
WO2005120200A3 (en)	2007-07-26	Amine compounds and inhibiting neurotransmitter reuptake